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Key Points 
Question: Can survival endpoints for pre-diagnosis Huntington's disease (HD) trials be 
developed to provide feasible sample sizes? 
Findings: Progression-free survival using a composite of motor diagnosis or a HD 
progression event yields much smaller sample sizes than using the event of motor 
diagnosis alone. The HD progression events show good external validity when applied 
to an independent study. 
Meaning: Progression-free survival provides feasible sample sizes for clinical trial 
planning with HD gene expansion mutation carriers who have not yet received a motor 
diagnosis. 
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Tweet 
Progression-free survival drastically reduces the sample size required for planning clinical 
trials in Huntington’s disease.  
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Abstract 
Importance: Predictive genetic testing in Huntington's disease (HD) enables 
therapeutic trials in HD gene expansion mutation carriers prior to motor diagnosis. 
Progression-free survival (PFS) is defined as the composite of motor diagnosis or a HD 
progression event, whichever comes first. 
Objective: Determine if PFS provides feasible sample sizes for trials with mutation 
carriers who have not yet received a motor diagnosis. 
Design: Pre-diagnosis mutation carriers are analyzed from the Track-HD (collected 
2008-2011) and Track-On (collected 2011-2014) cohort studies, with up to 7 years of 
follow-up. Clinically meaningful change of a Unified Huntington's Disease Rating Scale 
(UHDRS) variable is used to define a progression event. Results are externally 
validated with data from the Cooperative Huntington Observational Research Trial 
(COHORT; collected 2006-2011) cohort study. Required sample size is estimated for a 
two-arm pre-diagnosis clinical trial. 
Setting: The Track studies are longitudinal cohort studies conducted like clinical trials, 
but without intervention, with four sites. COHORT is a longitudinal cohort study with 38 
sites. 
Participants: Track had 167 pre-diagnosis mutation carriers and 156 non-carriers. 
Inclusion criteria were 18 to 65 years of age, toleration of MRI/biosample collection, no 
major psychiatric disorder/head injury, no therapeutic trial enrollment, and no limiting 
medical conditions. Non-carriers were age- and gender-matched spouses or partners of 
participants or non-carrier siblings. COHORT had 366 pre-diagnosis mutation carriers 
recruited with broader inclusion criteria (wider age range, no imaging). 
Main outcomes and measures: The primary endpoint is PFS. HD progression events 
are defined for the UHDRS total motor score, total functional capacity, symbol digit 
modalities test, and Stroop word test. 
Results: PFS survival curves of the Track mutation carriers (N = 156, 56% female, 
mean age = 40.06) show good external validity with the COHORT mutation carriers (N = 
6  
366, 63% female, mean age = 42.21) after adjusting for initial progression. For required 
sample size, PFS with motor diagnosis or TMS progression requires about 4 times 
fewer participants than motor diagnosis alone. Including additional cognitive progression 
events further reduces the number.  
Conclusions and Relevance: Reasonably sized pre-diagnosis HD trials can be 
planned with PFS and there is evidence of generalization of the approach. 
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Introduction 
Huntington’s disease (HD) is a devastating neurodegenerative disorder caused by a 
cytosine-adenine-guanine (CAG) expansion on the HTT gene of chromosome 41. HD is 
autosomal dominant with reduced penetrance for 36-39 repeats, and full penetrance for 
≥ 40 repeats2. Progression leads to a triad of signs and symptoms including motor, 
cognitive, and behavioral features3. A reliable predictive genetic test is available that 
can be used to establish whether an individual is a HD gene expansion mutation carrier 
prior to the emergence of any signs or symptoms. Early identification of carrier status 
enables trials to examine whether a therapeutic intervention might prevent or delay the 
pathological processes that lead to disease onset. 
A landmark event in HD is motor diagnosis, which is determined after the standard 
motor examination scored with the Unified Huntington's Disease Rating Scale 
(UHDRS)4. Motor diagnosis is defined as the highest rating on the UHDRS Diagnostic 
Confidence Level (DCL) that states the rater is at least 99% confident that the motor 
abnormalities displayed by the patient are unequivocal signs of HD. Despite the 
prominent role of motor diagnosis in HD research, there is a reluctance to use it as an 
endpoint in clinical trials2. The reason is that HD is a slow progressing disease and 
there are a small number of motor diagnosis events for cohorts that are followed over 
the short periods typical of clinical trials. 
We are reaching a time in HD therapy development when preventative clinical trials for 
mutation carriers who are not yet diagnosed are being planned. It is crucial to have 
better defined endpoints with this population over time periods that are feasible and 
cost-effective. The number of events can be increased by considering a secondary 
variable that is correlated with the definitive event of motor diagnosis, but has a faster 
rate of change. This alternative approach is known as progression-free survival (PFS), 
which is widely used in oncology trials5–7. PFS is the time elapsed since treatment 
initiation to the first event of HD progression or motor diagnosis, whichever comes first. 
The goal of this study is to examine PFS using data from 7 years of the Track 
observational study8–10 and evaluate the extent of reproducibility using data from a 
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separate independent study. Our hypothesis is that PFS will provide sufficient events for 
the planning of feasible pre-diagnosis clinical trials and show reasonable generalization. 
Methods 
Study population 
Primary analysis involved HD gene expansion mutation carriers and non-carriers from 
two phases of the Track study: Track-HD and Track-On. Track-HD is a longitudinal 
cohort study of pre-diagnosis and post-diagnosis mutation carriers, and healthy non-
carriers, with four sites in four countries (CAN, FRA, GBR, NE), and data collected 
2008-20118–10. Inclusion criteria were: 18 to 65 years of age; toleration of MRI and 
biosample collection; absence of major psychiatric disorder or history of significant head 
injury; not active in an experimental therapeutic trial; and no comorbid medical 
conditions preventing assessment. Non-carriers were selected from spouses or partners 
of carriers or non-carrier siblings. Non-carriers were age- and gender-matched to the 
carriers. 
Track-On is a longitudinal cohort study of mutation carriers and non-carriers, most of 
whom transitioned from Track-HD. 74% of the pre-diagnosis carriers and 64% of the 
non-carriers transitioned over to Track-On, and data collection spanned 2011-2014. 
Participants who transitioned over could have a maximum of 7 years of data. Table 1 
shows descriptive statistics for key variables at study entry (baseline) by carrier status. 
The external validation involved participants from the Cooperative Huntington 
Observational Research Trial (COHORT)11. COHORT is a longitudinal cohort study of 
HD gene expansion mutation carriers and non-carriers with 38 sites in three countries 
(AUS, CAN, USA), and data collected 2006-2011. Enrollment was open to people who 
had tested positive for the HD gene expansion mutation (pre-diagnosis or post-
diagnosis), or people who were untested but had a family history of HD. Non-carriers 
were family members verified by genetic testing to not have the expansion mutation. 
Only confirmed pre-diagnosis mutation carriers were considered for the validation 
analysis. Table 1 shows descriptive statistics for the COHORT sample along with 
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statistical comparisons to the Track carrier group. It is noted that the COHORT sample 
is significantly more progressed at baseline, as indicated by the clinical measures. 
Standard protocol approvals, registrations, and patient consents 
Study activities were reviewed and approved by local ethics committees (for Track) and 
institutional review boards (for COHORT). Informed consent according to the 
Declaration of Helsinki was obtained for each participant, including consent for the 
distribution of de-identified data for research purposes. 
Measures 
PFS requires a definitive endpoint, which is motor diagnosis. PFS also requires at least 
one secondary variable that is correlated with motor diagnosis, but potentially has a 
faster rate of change. The secondary variables considered here are the UHDRS total 
motor score (TMS), total functional capacity (TFC), symbol digit modalities test (SDMT), 
and Stroop word test (SWT).  
Endpoints 
Two types of survival endpoints are examined. The endpoint for traditional survival 
analysis is motor diagnosis (DCL = 4), and time to first occurrence is analyzed. PFS is a 
type of composite event that is triggered by either a progression event or motor 
diagnosis, whichever comes first. Thus, the time to the composite event is used for the 
PFS survival analysis. 
The progression event is a change from baseline of sufficient size to be deemed 
important, referred to as clinically meaningful change (CMC)13. Statistical methods for 
CMC estimation are described below. A progression event occurs for an individual if the 
change on the secondary variable meets or exceeds the CMC. For example, consider 
CMC = 3 for the TMS, and an individual has four time points with TMS = 8, 9, 12, 13, at 
baseline (0), 1, 2, and 3 years of follow-up. The TMS difference from baseline is 0, 1, 4, 
5, and we assume that DCL = 4 does not occur. The third and fourth values meet the 
criterion for a progression event, and time to the PFS event is 2 years because it is the 
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first instance of the progression event (time points after the event are ignored). PFS 
requires the composite event to occur after baseline; if there is no composite event over 
the observed epoch, the individual is considered right-censored, meaning the composite 
event happens sometime in the future. 
Statistical Analysis 
Clinically Meaningful Change (CMC) 
Track data is used to develop the CMC. In order for the CMC to accurately reflect 
disease effects as opposed to normal aging effects, our approach is to use an extreme 
score based on analysis with only the non-carriers. Change from baseline is computed 
for each follow-up time, which represents change due to natural aging (though there are 
practice effects for SDMT and SWT). Extremes of these changes are computed based 
on quantile mixed models for follow-up after baseline. The quantile mixed model 
accounts for the dependency due to repeated measures, but unlike traditional mixed 
models, a quantile is estimated as a function of time rather than the mean14. Change 
from baseline is regressed onto time on study, age at baseline, and their interaction. 
The 99th quantile is estimated for TMS because an increase from baseline indicates 
greater HD progression. Conversely, the 1st quantile is estimated for TFC, SDMT, and 
SWT because a decrease from baseline indicates greater progression. 
External Validation 
To assess the replicability (generalizability) of the endpoints, the CMC developed in 
Track is applied to the COHORT data. Mutation carriers from both studies are 
combined, study membership is coded, and then the survival profiles of the studies are 
compared using two statistical methods. The first method is the Wald test of study 
difference (𝑧𝑧-test) using Cox regression, and the second method is the likelihood ratio 
test of study difference based on smoothed cubic spline survival models15. The null 
hypothesis for both tests is that the survival curves of the studies are equivalent, 
possibly adjusting for covariates. Thus, evidence of the reproducibility of the PFS 
survival curves based on the Track CMC will be provided if there is no statistically 
significant study difference (significance is defined as 𝑝𝑝 < 0.05 for all results). Spline 
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modeling has the advantage of providing smooth survival curves that are not unduly 
affected by final times being event times (see Figure 1). Study differences are examined 
without and with adjustment for covariates. The covariates are all baseline variables that 
show a significant study difference from Table 1, except for follow-up. 
Required Sample Size 
A popular test of the equivalence of survival curves among groups is the log-rank test16. 
Sample size can be estimated from standard formulas when testing the null hypothesis 
of equivalent survival curves, under the assumptions of proportional hazards and 
exponentially distributed survival times17. Sample size estimates for the log-rank test 
require an estimate of the survival proportion at study end. Survival proportions are 
estimated based on the cubic spline survival curves. Sample sizes are estimated using 
the conventional type I error rate of 5% (two-tailed test), and type II error rate of 20% 
(power = 80%). Estimates are for a 3-year two-arm parallel trial with equal group sample 
size. In order to allow for attrition, the total sample size, 𝑁𝑁, is adjusted by the dropout 
rate, 𝑤𝑤. The adjustment for dropout is 𝑁𝑁𝑤𝑤 = 𝑁𝑁/(1− 𝑤𝑤), where 𝑤𝑤 = 0,  0.10,  0.20. 
To provide a benchmark for judging the performance of the non-parametric log-rank 
test, sample size is also estimated using the two-group Mann-Whitney-Wilcoxon 
(MWW) test of TMS at only the last time point. The MWW is a test of difference in group 
TMS medians when the group distributions are identical except for a location shift18. 
When the assumptions of the MWW test hold, it is more efficient than the log-rank test 
and will yield a smaller sample size19. 
The treatment effect size is defined as the hypothetical proportion reduction (𝜋𝜋) in the 
treatment TMS mean (𝜇𝜇𝑇𝑇) relative to the placebo mean (𝜇𝜇𝑃𝑃) at the study terminus; 𝜋𝜋 =|(𝜇𝜇𝑃𝑃 − 𝜇𝜇𝑇𝑇)|/𝜇𝜇𝑃𝑃. The Track pre-diagnosis mutation carriers are treated as a proxy for the 
placebo group, and the hypothetical improvement in the treatment TMS mean is 
computed as 𝜇𝜇𝑇𝑇 = 𝜇𝜇𝑃𝑃(1− 𝜋𝜋). The quantity 𝜋𝜋 is related to Cohen's 𝑑𝑑 as 𝑑𝑑 = 𝜇𝜇𝑃𝑃(𝜋𝜋)/𝜎𝜎, 
where 𝜎𝜎2 is the common group variance. For the Track data, the 3 year visit mean and 
SD is estimated to be 𝜇𝜇𝑃𝑃 = 6.59 and ?^?𝜎 = 5.86, so that a 50% TMS mean reduction 
produces 𝑑𝑑 = 6.59(0.50)/5.86 = 0.56. Cohen's 𝑑𝑑 is not appropriate for the non-
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parametric log-rank test and MWW test. Therefore, Cohen's 𝑑𝑑 is transformed into the 
area under the curve (AUC) of the ROC curve in medical diagnostic testing20. AUC is a 
non-parametric effect size on the 0-1 scale and has a convenient probability 
interpretation for the log-rank test. AUC is the probability that a randomly sampled 
patient from the treatment group will delay a HD progression event longer than a 
randomly sampled patient from the placebo group19. There is no treatment effect when 
𝐴𝐴𝐴𝐴𝐴𝐴 = 0.50 because there is an equal chance of longer delay for both groups; it is only 
when 𝐴𝐴𝐴𝐴𝐴𝐴 > 0.50 that we have longer delay for the treatment group. For the 
aforementioned 50% TMS mean reduction (with 𝑑𝑑 = 0.56), the effect size is 𝐴𝐴𝐴𝐴𝐴𝐴 = 0.65. 
Results 
Results of the CMC analysis using the Track non-carrier group are shown in Table 2. 
The table shows the point estimates and 95% bootstrap confidence intervals (CIs) for 
select ages. Because the UHDRS variables take only integer values, the CMC point 
estimates can be rounded up ignoring sign. For example, the CMC for TMS is 3 for age 
30 and 35, and 4 for age 40-50, etc. The CMC for TFC is -1 (loss of 1) for age 35 and 
older.   
Results of the study survival curve comparison are presented in Table 3. Kaplan-Meier 
curves and fitted spline curves without covariate adjustment are shown in Figure 1. 
Kaplan-Meier probabilities descend to 0 for some curves because the final time is an 
event time (spline curves are unaffected by this occurrence). Figure 1 shows that 
individuals from COHORT have a greater risk of an event than those from Track, with 
the TMS curves being most similar. Likewise, the upper portion of Table 3 indicates 
significant study survival curve differences without covariate adjustment for all endpoints 
except TMS. The bottom portion of Table 3 shows that after adjusting for baseline 
variables, the study differences are no longer significant, except for SDMT (which is not 
considered further for this reason). 
Estimated total sample size is shown in Table 4 for a hypothetical 3-year parallel arm 
clinical trial with 10% attrition. As expected, traditional survival analysis based on DCL 
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has the largest estimated sample size. PFS with TMS progression shows substantially 
lower sample sizes than DCL alone, being almost 4 times smaller for most effect sizes. 
However, PFS based on TMS progression has sample sizes that are approximately 1.5 
times larger than the smallest possible sizes of the MWW test. Combining TMS with 
SWT progression lowers the sample sizes to the point of being only about 1.3 times 
larger than the MWW test. 
Discussion 
The goal of this study was to define clinically meaningful change (CMC) and a HD 
progression event for use in preventative trials with HD gene expansion mutation 
carriers prior to motor diagnosis. The Track study is favorable for CMC analysis as it 
was conducted like a clinical trial, but without an active treatment group8–10. CMC 
developed in Track was used to define progression-free survival (PFS) endpoints, and 
for the most part, the survival curves were found to be similar for the COHORT data, 
especially after adjusting for progression differences at study entry. Therefore, the CMC 
values developed here appear to be reasonable general indexes for defining HD 
progression events in clinical trial planning. 
The required sample size for a clinical trial can be greatly reduced when a TMS 
progression event is used in combination with motor diagnosis, which is consistent with 
our explicit hypothesis. Motor diagnosis based on the DCL is perhaps the closest the 
field has to a gold standard for a landmark progression event in HD. As expected, 
survival analysis with time to motor diagnosis yielded the largest required sample size, 
whereas the PFS endpoints offered substantial reduction. If one wants to retain the 
definitive outcome of a motor diagnosis while providing enough HD progression events 
for a reasonably sized trial, then PFS can help. TMS progression, for example, requires 
approximately 4 times fewer participants for the range of effect sizes considered. It is 
notable that PFS is approved by the FDA as a surrogate endpoint for cancer trials21. 
Such endorsement is an encouraging sign that PFS might eventually be successful in 
pivotal trials of HD. 
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The potential advantage of PFS is that it incorporates motor diagnosis and produces 
enough events to increase the feasibility of pre-diagnosis trials. This is not to say that 
PFS necessarily yields smaller sample sizes than traditional methods. PFS involves 
dichotomizing continuously measured UHDRS variables, which reduces information, 
and can lead to lower efficiency22. Our results show that though PFS can drastically 
lower the sample size as compared to using motor diagnosis alone, the sample size is 
still larger than a method that compares the TMS among groups at the last visit. 
Therefore, if efficiency is the only criterion for choosing an endpoint, then PFS may be 
less attractive than traditional methods. 
The primary appeal of PFS is that it is anchored to the event of motor diagnosis, which 
is a well-established landmark in the progression of HD. PFS may also be desirable 
because its effect size can be expressed as a probabilistic statement of potential patient 
benefit. For instance, AUC = 0.60 means that a given person in the treatment group has 
a 60-40 chance of delaying a HD progression event relative to a person in the untreated 
group. HD prevention therapy will likely be demanding for participants (e.g., repeated 
lumbar punctures), and treatment may only be desirable to pursue if the chance of 
benefit is sufficient in the minds of both the participants and researchers. The AUC 
effect size provides a clear means of articulating a minimum potential benefit. 
The question remains as to what minimum AUC is acceptable. Pilot data can provide an 
indication of effect sizes that are in reach, or HD stakeholders can decide on a minimum 
probability. We offer the opinion that AUC values smaller than 0.60 seem to get 
uncomfortably close to a 50-50 chance of delay, which is just a coin flip's chance. 
Furthermore, our results indicate that AUC = 0.60 requires total 𝑁𝑁 = 364 for the TMS 
endpoint in a two-arm study with 10% dropout. When AUC is less than 0.57, more than 
500 participants total will be required. The feasibility of a particular sample size depends 
on many factors, but we feel that planning for a study with no greater than 400 
participants will increase the likelihood of a trial being conducted. The lower bound of 
AUC = 0.60 is consistent with this goal. 
The PFS endpoint is a composite by definition. There is recent increased interest in 
composite endpoints because of the potential of smaller studies and lower costs25. An 
15  
advantage of PFS is that the composite is defined in a clear manner, not requiring 
weights for combining variables. Because key variables are collected at the standard 
UHDRS exam, it is feasible to use such composite endpoints at little cost. The caveat 
here, as with any composite endpoint, is a potential lack of clarity regarding the nature 
of the effects. PFS will not distinguish an individual who has a TMS progression event 
from another who has a SWT event, for example. Assuming a treatment has a benefit, 
the benefit must be reported in terms of potentially delaying the package of HD 
progression events. Perhaps PFS using TMS is most clear, as the composite focuses 
only on motor signs and a treatment benefit can be expressed broadly as a delay in HD 
motor progression. 
A particular CMC threshold does not necessarily speak to the importance of the 
progression event in the experience of a mutation carrier. In clinical trials where PFS is 
used, it is typical to have an expert panel convened to confirm the appropriateness of 
the CMC as the basis for a progression event. For example, panels of oncology experts 
have been convened to determine the criteria for a solid tumor increase to define a 
tumor progression event, resulting in the Response Evaluation Criteria in Solid Tumors 
(RECIST) guidelines for cancer trials26,27. Our CMC results are not meant to substitute 
for an expert panel; they are offered as data-based results that might be informative to 
such a panel. 
The focus of this study is on preventative trials involving confirmed mutation expansion 
carriers who have not yet reached motor diagnosis. It is possible that a mutation carrier 
might not have a motor diagnosis at pre-screening, but have a diagnosis at the first visit. 
This is problematic because such a person must be analyzed according to the intent-to-
treat principle, even though they have a 0 event time that is uninformative. An approach 
to address this problem is to disregard DCL status in the analysis and only use time to 
the TMS progression event as the outcome. The TMS progression event is defined 
relative to study entry, so there will always be an analyzable event time. Analysis with 
this modified endpoint is called time-to-progression analysis5. Practically speaking, 
there is no difference in the number of events for time-to-progression and PFS in our 
analysis (results not presented), because every individual who is eventually assigned a 
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motor diagnosis has an earlier TMS progression event. Thus, motor diagnosis does not 
contribute to the event status of PFS, and it is equivalent to time-to-progression. The 
drawback however, is that the method does not have the definitive endpoint of motor 
diagnosis (motor diagnosis is ignored). 
The finding that the mutation carriers of COHORT were more progressed than those of 
Track at study entry is likely due to differences in recruitment strategy. Track-HD 
explicitly aimed to recruit pre-diagnosis carriers who were relatively far from motor 
diagnosis, whereas COHORT did not. The external validation considered mutation 
carriers in both studies who were willing to undergo genetic testing. We provide 
evidence that the participants from the two studies are similar after adjusting for 
baseline progression. But it is unknown if our results generalize to the broader HD 
population because most at-risk individuals do not undergo genetic testing28. 
In conclusion, minimum values are proposed for assessing clinically meaningful change 
over time for HD gene expanded mutation carriers who have not yet received a motor 
diagnosis. The change values can be used to define progression events that are easy to 
combine, yield trials of reasonable size, and may apply across studies. The approach is 
especially appealing when a researcher wants to examine whether a treatment delays 
motor onset. 
17  
Acknowledgments 
Track-HD was supported by the CHDI Foundation, a not-for-profit organisation 
dedicated to finding treatments for Huntington’s disease. We thank the Track-HD study 
participants and their families. We also acknowledge the support of the National 
Institute for Health Research University College London Hospitals Biomedical Research 
Centre and the Manchester Biomedical Research Centre. 
Samples and/or data from the COHORT Study, which received support from HP 
Therapeutics, Inc., were used in this study. We thank the Huntington Study Group 
COHORT investigators and coordinators who collected data and/or samples used in this 
study, as well as participants and their families, who made this work possible. 
The Track-HD investigators are: Australia—C Campbell, M Campbell, E Frajman, I 
Labuschagne, C Milchman, A O'Regan, J Stout (Monash University, Victoria). 
Canada—A Coleman, R Dar Santos, J Decolongon, A Sturrock (University of British 
Columbia, Vancouver). France—E Bardinet, C Jauffret, D Justo, S Lehericy, C Marelli, 
K Nigaud, R Valabrègue (APHP, Hôpital Salpêtriere, Paris). Germany—N Bechtel, S 
Bohlen, R Reilmann (University of Münster, Münster); B Landwehrmeyer (University of 
Ulm, Ulm); A Hoffman, P Kraus (University of Bochum, Bochum). Netherlands—SJA 
van den Bogaard, E M Dumas, J van der Grond, EP t'Hart, C Jurgens, M-N Witjes-Ane 
(Leiden University Medical Centre, Leiden). UK—N Arran, J Callaghan, D Craufurd, C 
Stopford (St Mary's Hospital, Manchester); C Frost, R Jones (London School of Hygiene 
and Tropical Medicine, London); H Crawford, N C Fox, C Gibbard, N Hobbs, N Lahiri, I 
Malone, R Ordidge, G Owen, T Pepple, J Read, M J Say, D Whitehead (University 
College London, London); S Keenan (Imperial College London, London); D M Cash 
(IXICO, London); C Berna, S Hicks, C Kennard  (University of Oxford, Oxford). USA— T 
Acharya, E Axelson, H Johnson, C Wang, (University of Iowa, Iowa City, IA); B 
Borowsky (CHDI Foundation, NY); S Lee, W Monaco (Massachusetts General Hospital, 
Harvard, MA); C Campbell, S Queller, K Whitlock (Indiana University, IN). 
The Track-On investigators are: Australia—I Labuschagne (Monash University, 
Victoria); Canada—A Coleman, J Decolongon, M Fan, T Petkau (University of British 
18  
Columbia, Vancouver). France—C Jauffret, D Justo, S Lehericy, K Nigaud, R 
Valabrègue (ICM and APHP, Hôpital Salpêtriere, Paris).  Germany—N Weber (George 
Huntington Institute, Münster); I Mayer, M Orth (University of Ulm, Ulm). Netherlands—
A Schoonderbeek, EP t'Hart, (Leiden University Medical Centre, Leiden). UK—D 
Craufurd (St Mary's Hospital, Manchester); A Cassidy, C Frost, R Keogh (London 
School of Hygiene and Tropical Medicine, London); C Berna, H Crawford, M Desikan, R 
Ghosh, D Hensman Moss, E Johnson, P McColgan, G Owen, M Papoutsi, J Read, A 
Razi, D Mahaleskshmi (University College London, London). USA—H Johnson 
(University of Iowa, Iowa City, IA); B Borowsky (CHDI Foundation, NY).  
Financial Disclosures 
Jeffrey D. Long has a consulting agreement with NeuroPhage, is a paid consultant for 
Roche Pharma and Azevan Pharmaceuticals, and receives funding from CHDI, Michael 
J. Fox Foundation, and NIH. 
James A. Mills has no financial disclosures. 
Blair R. Leavitt reports research grants from Teva, CHDI, and Lifemax. Personal 
Consulting fees from Roche, uniQure, Novartis, Lifemax and Raptor. 
Alexandra Durr received research grants from the French Agency for Research, French 
Ministry for Social affairs and Health, Pfizer Inc. and Annapurna Therapeutics. She 
holds partly a patent B 06291873.5 on Anaplerotic therapy of Huntington’s disease and 
other polyglutamine diseases. 
Raymund A. Roos received grants from The Gossweiler Foundation and TEVA, both via 
the LUMC administration. He is an advisor for UniQure. 
Julie C. Stout has served on an advisory board for Roche, has consulted to Prana 
Biotechnology, is treasurer and board member for the Huntington's Study Group, Inc., 
and conducts business implementing cognitive assessments at Stout Neuropsych Pty 
Ltd, with contracts from Teva, Vaccinex, Omeros, and Ionis. 
Ralf Reilmann is founding director and owner of the George-Huntington-Institute, a 
private research institute focused on clinical and preclinical research in Huntington’s 
19  
disease, and QuantiMedis, a clinical research organization providing Q-Motor 
(quantitative motor) services in clinical trials and research. He holds appointments at the 
Dept. of Radiology of the University of Muenster and at the Department of 
Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University 
of Tuebingen. He provided consulting services, advisory board functions, clinical trial 
services, quantitative motor analyses, and/or lectures for Teva, Pfizer, uniQure, Ipsen, 
Vaccinex, Novartis, Raptor, Omeros, Siena Biotech, Neurosearch Inc., Lundbeck, 
Medivation, Wyeth, ISIS Pharma, Link Medicine, Prana Biotechnology, MEDA Pharma, 
Temmler Pharma, Desitin, AOP Orphan, and the Cure Huntington’s Disease Initiative 
Foundation. He received grant support from the High-Q-Foundation, the Cure 
Huntington’s Disease Initiative Foundation (CHDI), the Deutsche 
Forschungsgemeinschaft (DFG), the European Union (EU-FP7 program), the 
Bundesministerium fur Bildung und Forschung (BMBF), the Deutsches Zentrum fur 
Neurodegeneration und Entzundung (DZNE), and the European Huntington’s Disease 
Network (EHDN). 
Bernhard Landwehrmeyer has provided consulting services, advisory board functions, 
clinical trial services and/or lectures for Allergan, Alnylam, Aventis, Amarin, AOP 
Orphan Pharmaceuticals AG, Bayer Pharma AG, Desitin, Genzyme, GlaxoSmithKline, 
Hoffmann-La Roche, Ipsen, ISIS Pharma, Lundbeck, Neurosearch Inc, Medesis, 
Medivation, Medtronic, Novartis, Pfizer, Prana Biotechnology, Raptor Pharmaceuticals, 
Sangamo/Shire, Sanofi-Aventis, Siena Biotech, Temmler Pharma GmbH, Trophos, and 
TEVA and has received research grant support from the CHDI Foundation, the 
Bundesministerium fur Bildung und Forschung (BMBF), the Deutsche 
Forschungsgemeinschaft (DFG), the European Commission (EU-FP7). His study site 
Ulm has received compensation in the context of the observational REGISTRY-Study of 
European Huntington's Disease Network (EHDN). 
Sarah Gregory has no financial disclosures. 
Rachael I. Scahill has no financial disclosures. 
20  
Douglas R. Langbehn received research funding from CHDI, from the Neurology 
Institute of the University college of London, and from NIH/NIDA via grant 
5R01AA021165-03. He is also a paid statistical consultant for Roche and Voyager 
pharmaceutical companies for Huntington's disease clinical trial design. 
Sarah J. Tabrizi has served on advisory boards or had consultancies with F. Hoffmann-
La Roche Ltd, Ionis Pharmaceuticals, Ixico Technologies, Shire Human Genetic 
Therapies, Takeda Pharmaceuticals International and TEVA Pharmaceuticals. All 
honoraria paid for these consultancies and advisory boards go to UCL, Dr. Tabrizi's 
employer. 
 
 
21  
References 
1. Ross CA, Tabrizi SJ. Huntington’s disease: From molecular pathogenesis to clinical 
treatment. Lancet Neurology. 2011;10:83–98.  
2. Huntington Study Group PHAROS Investigators. Clinical-genetic associations in the 
prospective Huntington at risk observational study (PHAROS). JAMA Neurology. 
2016;73:102–110.  
3. Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: Natural history, biomarkers 
and prospects for therapeutics. Nature Reviews Neurology. 2014;10:204–216.  
4. Huntington Study Group. Unified Huntington’s Disease Rating Scale: Reliability and-
consistency. Movement Disorders. 1996;11:136–142.  
5. Booth CM, Eisenhauer EA. Progression-free survival: Meaningful or simply 
measureable? Journal of Clinical Oncology. 2012;30:1030–1033.  
6. Saad ED, A. K. Progression-free survival and time to progression as primary 
endpoints in advanced breast cancer: Often used, sometimes loosely defined. Annals of 
Oncology. 2009;20:460–464.  
7. Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary 
measure of efficacy for advanced NSCLC therapy? Annals of Oncology. 2010;21:2324–
2332.  
8. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of 
Huntington’s disease in the longitudinal Track-HD study: Cross-sectional analysis of 
baseline data. Lancet Neurology. 2009;8:791–801.  
9. Tabrizi S, Scahill R, Durr A, et al. Biological and clinical changes in premanifest and 
early stage Huntington’s disease in the Track-HD study: The 12-month longitudinal 
analysis. Lancet Neurology. 2011;10:31–42.  
22  
10. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and 
disease onset in premanifest and early-stage Huntington’s disease in the Track-HD 
study: Analysis of 36-month observational data. Lancet Neurology. 2013;12:637–649.  
11. Dorsey ER, the Huntington Study Group COHORT Investigators. Characterization of 
a large group of individuals with huntington disease and their relatives enrolled in the 
COHORT study. PLoS ONE. 2012;7:1–10.  
12. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington’s 
disease. Neurology. 2000;54:452–458.  
13. Crosby RD, L. KR, R. WG. Defining clinically meaningful change in health-related 
quality of life. Journal of Clinical Epidemilogy. 2003;56:395–407.  
14. Geraci M, Bottai M. Linear quantile mixed models. Statistics and Computing. 
2014;24:461–479.  
15. Royston P, Parmar MKB. Restricted mean survival time: An alternative to the 
hazard ratio for the design and analysis of randomized trials with a time-to-event 
outcome. BMC Medical Research Methodology. 2013;13:152–162.  
16. Cox DR, Oakes D. Analysis of survival data. London: Chapman; Hall; 1984.  
17. Machin D, Campbell MJ, Tan SB, Tan SH. Sample size tables for clinical studies. 
Hoboken, NJ: Wiley-Blackwell; 2009.  
18. Noether GE. Sample size determination for some common nonparametric tests. 
Journal of the American Statistical Association. 1987;82:645–647.  
19. Rahardja D, Zhao YD. Unified sample size calculations using the competing 
probability. Statistics in Biopharmaceutical Research. 2009;1:323–327.  
20. Acion L, Peterson JJ, Temple S, Arndt S. Probabilistic index: An intuitive non-
parametric approach to measuring the size of treatment effects. Statistics in Medicine. 
2008;25:591–602.  
23  
21. FDA. Guidance for industry: Clinical trial endpoints for the approval of cancer drugs 
and biologics, clinical-medical guidances. [online]. U.S. Department of Health; Human 
Services; 2007. Accessed at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guida
nces/UCM259421.pdf. 
22. Wason JMS, Dentamaro A, Eisen TG. The power of phase II end-points for different 
possible mechanisms of action of an experimental treatment. European Journal of 
Cancer. 2015;51:984–992.  
23. Long JD, Paulsen JS, Marder K, Zhang Y, Kim J, Mills JA. Tracking motor 
impairments in the progression of Huntington’s disease. Movement Disorders. 
2014;29:311–319.  
24. Paulsen JS, Smith MM, Long JD. Cognitive decline in prodromal Huntington: 
Disease: Implications for clinical trials. Journal of Neurology, Neurosurgery, and 
Psychiatry. 2013;84:1233–1239.  
25. Tomlinson G, Detsky AS. Composite end points in randomized trials: There is no 
free lunch. Journal of the American Medical Association. 2010;303:267–268.  
26. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in 
solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 
2009;45:228–247.  
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the 
response to treatment in solid tumors. Journal of the National Cancer Institute. 
2000;92:205–216.  
28. Shoulson I, Young AB. Milestones in Huntington’s disease. Movement Disorders. 
2011;26:1127–1133.  
  
24  
Table 1.Descriptive statistics for variables measured at study entry (baseline). Mean 
(SD) for quantitative variables and count (percentage) for categorical variables. 
Statistical tests are for CAG expanded study participants (Track vs. COHORT). 
 
Track  
Non-
Carriers 
Track 
Mutation 
Carriers 
COHORT 
Mutation 
Carriers 
Statistica p-value 
N 156 167 366   
Female 87 (56%) 93 (56%) 229 (63%) -1.50 0.132 
Age 
45.58 
(10.30) 
40.06 
(8.92) 
42.21 
(12.48) 
-2.00 0.046 
CAG 
Expansion 
 
43.22 
(2.42) 
42.37 
(2.80) 
3.35 <.001 
Total Motor 
Score 
1.42 (1.65) 3.01 (2.28) 6.23 (8.57) -4.78 <.001 
Total 
Functional 
Capacity 
12.99 
(0.11) 
12.86 
(0.51) 
12.36 
(1.54) 
4.13 <.001 
Symbol Digit 
Modalities 
Test 
52.49 
(9.46) 
51.66 
(10.17) 
44.99 
(12.17) 
6.17 <.001 
Stroop Word 
Test 
105.35 
(16.95) 
99.95 
(16.86) 
90.76 
(19.89) 
5.18 <.001 
Follow-Up 
(Years) 
4.00 (2.19) 4.22 (2.11) 2.27 (1.02) 14.41 <.001 
Note. az-test for female and t-test (df = 531) for all others; CAG = cytosine-adenine-
guanine. 
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Table 2. Clinically meaningful difference point estimate (95% CI) for a hypothetical 3-year trial. Each point estimate is the 
extreme quantile (1% or 99%) based on the Track non-mutation carriers (controls). 
 Age 
Variable 30 35 40 45 50 55 60 65 70 
Total Motor 
Score 
2.30 
[1.35,3.21] 
2.72 
[1.64,3.77] 
3.15 
[1.95,4.31] 
3.57 
[2.23,4.89] 
4.00 
[2.46,5.51] 
4.43 
[2.72,6.11] 
4.85 
[2.95,6.72] 
5.28 
[3.20,7.32] 
5.70 
[3.48,7.92] 
Total Functional 
Capacity 
-0.00 
[-0.04,0.01] 
-0.02 
[-0.06,-0.01] 
-0.03 
[-0.09,-0.01] 
-0.04 
[-0.12,-0.01] 
-0.06 
[-0.15,-0.01] 
-0.07 
[-0.19,-0.02] 
-0.08 
[-0.22,-0.01] 
-0.10 
[-0.25,-0.02] 
-0.11 
[-0.28,-0.02] 
Symbol Digit 
Modalities Test 
-1.78 
[-3.33,-0.11] 
-3.70 
[-5.05,-2.16] 
-5.62 
[-7.32,-4.10] 
-7.54 
[-9.69,-5.78] 
-9.46 
[-12.12,-
7.17] 
-11.38 
[-14.67,-
8.54] 
-13.30 
[-17.32,-
9.88] 
-15.21 
[-19.93,-
11.17] 
-17.13 
[-22.59,-
12.44] 
Stroop Word 
Test 
-10.39 
[-17.04,-6.10] 
-13.28 
[-20.11,-8.85] 
-16.16 
[-23.18,-
11.38] 
-19.05 
[-26.86,-
13.49] 
-21.94 
[-30.54,-
15.60] 
-24.83 
[-34.07,-
17.60] 
-27.72 
[-37.73,-
19.72] 
-30.61 
[-41.49,-
21.64] 
-33.50 
[-45.25,-
23.46] 
26  
Table 3. Training and test study survival comparisons for various endpoints. Upper portion shows the 
results for study difference not adjusting for covariates, and the lower portion shows study difference 
adjusting for covariates. 
  Cox Model Spline Model 
Endpoint B exp(B) SE Z p Chisq p 
Study Difference Only       
Diagnostic Confidence 
Level (DCL) 
-0.79 0.45 0.22 -3.63 <.001 16.60 <.001 
Total Motor Score 
or DCL 
-0.15 0.86 0.13 -1.10 0.269 2.17 0.141 
Total Functional 
Capacity or DCL 
-0.71 0.49 0.18 -3.97 <.001 21.03 <.001 
Symbol Digit Modalities 
Test or DCL 
-0.55 0.58 0.16 -3.53 <.001 17.26 <.001 
Stroop Word Test 
 or DCL 
-0.62 0.54 0.18 -3.51 <.001 15.13 <.001 
Study Difference + Covariates       
Diagnostic Confidence 
Level (DCL) 
-0.11 0.90 0.25 -0.43 0.671 0.43 0.513 
Total Motor Score 
or DCL 
0.07 1.07 0.15 0.49 0.621 0.06 0.811 
Total Functional 
Capacity or DCL 
-0.29 0.75 0.20 -1.48 0.139 3.56 0.059 
Symbol Digit Modalities 
Test or DCL 
-0.45 0.64 0.17 -2.66 0.008 10.23 0.001 
Stroop Word Test 
 or DCL 
-0.34 0.72 0.19 -1.72 0.085 3.82 0.051 
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Note. Covariates are all significant variables (p < .05) from Table 1; Chisq has df = 1. 
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Table 4. Required total sample size (N) for a 3-year, two-arm parallel trial, as a function of trial condition and endpoint. 
Multiple response variables denote the composite event of progression-free survival. Calculations are based on equal 
group allocation, type I error rate = 5%, power = 80%, and 10% dropout. 
  Sample Size 
Condition 
Survival 
Analysis 
Progression-Free Survival Analysis 
MWW 
Test 
TX Effect AUC DCL 
TMS or 
DCL 
TFC or 
DCL 
SDMT or 
DCL 
SWT or 
DCL 
TMS or 
SWT or 
DCL 
Median 
25% 0.579 2376 646 1450 960 1381 573 468 
30% 0.594 1689 457 1030 681 980 406 327 
35% 0.610 1269 342 773 511 737 302 242 
40% 0.625 993 267 604 399 576 236 187 
45% 0.640 801 214 488 321 463 189 149 
50% 0.655 661 177 402 266 383 156 122 
55% 0.669 557 149 339 223 322 131 102 
60% 0.683 477 127 290 191 276 112 87 
65% 0.697 412 110 251 166 239 97 74 
70% 0.711 361 96 220 144 209 84 66 
75% 0.725 320 84 194 128 184 74 58 
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Note. TX = treatment; AUC = area under the curve; DCL = diagnostic confidence level; TMS = total motor score; TFC = 
total functional capacity; SDMT = symbol digit modalities test; SWT = Stroop word test; MWW = Mann-Whitney-Wilcoxon. 
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Figure 1. Kaplan-Meier survival curves (stepped) and cubic spline curves 
(smooth) by follow-up year and study for different survival endpoints. Curves are 
unadjusted for covariates. 
 
